Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Ifversen, Marianne  [Clear All Filters]
2023
Cseh A, Galimard J-E, De La Fuente J, Isgrò A, Zecca M, Garwer B, Biffi A, Aljurf M, Sundin M, Belendez C, et al. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. Br J Haematol. 2023.
Bader P, Poetschger U, Dalle J-H, Moser LM, Balduzzi ACristina, Ansari M, Buechner J, Güngör T, Ifversen M, Kriván G, et al. Low rate of nonrelapse mortality in under 4-year-olds with ALL given chemo-conditioning for HSCT: Phase III FORUM study. Blood Adv. 2023.
Hergel LLouise Fos, Kielsen K, Weischendorff S, Ifversen M, Kamari-Kany N, Møller HJon, Rittig S, Grønbæk H, Müller K. The macrophage activation marker sCD163 in acute and chronic graft-versus-host disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2023.
Mølgaard K, Kielsen K, Ifversen M, Met Ö, Svane IMarie, Müller K. Reduced mitochondrial respiration in peripheral T cells after paediatric heamatopoietic stem cell transplantation. Front Immunol. 2023;14:1327977.
Böhm S, Wustrau K, Schmid JPachlopnik, Prader S, Ahlman M, Yacobovich J, Beier R, Speckmann C, Behnisch W, Ifversen M, et al. Survival in primary hemophagocytic lymphohistiocytosis 2016-2021: etoposide is better than its reputation. Blood. 2023.